AstraZeneca, BMS in $400B Merger Talks, Could Redefine Pharma Landscape
AstraZeneca and Bristol Myers Squibb held early talks on a merger valued at roughly $400 billion, which would create one of the world’s largest drugmakers. The deal faces U.S. antitrust scrutiny and would give the UK‑based AstraZeneca a major foothold in the U.S. market.